Ipamorelin

Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor to trigger growth hormone release. It is described as relatively selective compared with older secretagogues, but it is not approved for human use and there is no adequate trial evidence for the body composition, recovery or anti-aging claims made for it.

Evidence-first summary of ipamorelin, a growth hormone secretagogue: what is known, why human outcome data is missing, regulatory status and risks.

A selective growth hormone secretagogue with almost no human outcome data.

Key takeaways

How it differs from GHRH analogues

GHRH analogues such as CJC-1295 act at the GHRH receptor. Ipamorelin acts at the ghrelin receptor. Both end in growth hormone release, through different doors, which is the rationale behind the combinations that circulate online.

What is missing

The published human record concerns hormone release and short-term tolerability. It does not include the outcome trials that would be needed to say whether ipamorelin changes muscle mass, fat mass, recovery or sleep in a meaningful way.

Risk framing

Appetite stimulation, glucose effects, unmonitored IGF-1 elevation and unregulated supply are the practical concerns.

Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.

Frequently asked questions

Is ipamorelin safer than older growth hormone peptides?

It is described as more selective in early research, but 'more selective' is not the same as demonstrated safety in sustained human use.

Is it approved for anything?

No. It is not an approved human medicine.

Why is it usually combined with another peptide?

Online protocols pair mechanisms to increase hormone release. Beiing does not publish combination or dosing guidance, and combined use has no human outcome evidence.

Related on Beiing

Sources

  1. PubMed - National Library of Medicine - NIH
  2. FDA - Bulk Drug Substances Used in Compounding Under Section 503A - U.S. Food and Drug Administration
  3. ClinicalTrials.gov - U.S. National Library of Medicine

Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.